БЕСПЛАТНЫЙ ПРОСМОТР ОТДЕЛЬНЫХ ОНЛАЙН МЕРОПРИЯТИЙ КОНГРЕССОВ ЕНА, ASCO, ICML

в рамках АСКО 2021

Guideline Updates and Real-World Experiences in CLL: Experts Review State-of-the-Art Evidence and Address Next Questions

CCO/NCCN | Multi-supported | Faculty – Weirda, Abramson, Mato

Virtual Live Date – June 8, 2021; 7-8:30 PM ET;

Registration Link: www.clinicaloptions.com/ChicagoNCCNCLL2021

New Standards for CLL Care With BTK Inhibitors: Using Evidence to Make Personalized Choices in Treatment-Naïve and Relapsed Disease

PeerView | Sole-supported | Faculty – Weirda, Lamanna, Rogers

Virtual Live Date – June 9, 2021; 6:30-8 PM ET;

Registration Link: www.PeerView.com/CLL21Live

Pushing the Boundaries in CLL: A Guide to the Convergence of Targeted Therapy, Novel Combinations and Precision Medicine in Patient Care

PeerView | Multi-supported I Faculty – Davids, Jain, Stephens

Virtual Live Date – June 14, 2021; 6:30 – 8 PM ET;

Registration Link: https://learn2.peerview.com/150206867_1/150206867_1_p1/stage1reg?Promocode=700&ProjectNumber=150206867_1

Consensus or Controversy? Clinical Investigators Provide Perspectives on the Current and Future Management of Patients with Multiple Myeloma, CLL and Hodgkin and Non-Hodgkin Lymphomas

RTP | Multi-supported I Faculty – Kahl, Gribben, Sehn

Virtual Live Date – June 29, 2021; 5-6:30 PM ET;

Registration Link: http://www.researchtopractice.com/Meetings/SummerWebinars21

в рамках ЕНА 2021

Thursday, June 10, 2021 – 8:30 – 10:00 AM CEST – (Live Webinar)

Evolving Therapeutic Strategies Using BTK Inhibitors in CLL: Guidance on a Selective Approach to Improve

Patient Outcomes

Med Ed Provider – CCO – Sole-Supported by AZ – Grant #64168177

Faculty: Ghia, Follows, LeBlond

Registration Link: http://clinicaloptions.com/EHA2021CLLJoin1

Anticipated Attendance: 600 June 10th; *Enduring will be launched following ICML (One grant was funded with CCO for both EHA and ICML)

Learning Objectives:

•Evaluate differences between first- and next-generation BTK inhibitors in terms of molecular characteristics, selectivity, preclinical data, approved indications, dosing, safety profile, and efficacy

•Identify patient candidates for BTK inhibitor-based therapy, in either treatment naïve or previously treated CLL

•Select optimal BTK inhibitor-based therapy for patients with CLL, taking into consideration guidelines, expert recommendation, and recent practice-changing clinical trial results

•Recognize and manage adverse events and toxicities associated with BTK inhibitor therapy to support adherence, appropriate dosing, quality of life, and continuation of treatment

•Assess ongoing clinical trials evaluating currently available and emerging BTK inhibitors (and BTK-based combinations) to aid clinical trial enrollment and predict new options in the clinic

В рамках конгресса ICML

Friday, June 18, 2021 – 12:00 – 1:30 PM CEST; (Pre-recorded session and live Q&A)

Evolving Therapeutic Strategies Using BTK Inhibitors in CLL: Guidance on a Selective Approach to Improve

Patient Outcomes

Med Ed Provider – CCO – Sole-Supported by AZ – Grant #64168177

Faculty: Ghia, Follows, LeBlond

Registration Link: https://clinicaloptions.com/ICML2021CLLJoin1

Anticipated Attendance: 200 June 18th; 5,000 for Enduring which will be marketed to both EHA and ICML meeting registrants and the wider CCO global oncology learner database

______________________________________________________

БЕСПЛАТНЫЙ ПРОСМОТР ОТДЕЛЬНЫХ ОНЛАЙН МЕРОПРИЯТИЙ КОНГРЕССОВ ЕНА, ASCO, ICML

Подписаться на рассылку

Похожие новости

Вход специалиста онкогематолога

Восстановление пароля

Зарегистрироваться на этом сайте

Подтвердить членство или вступить в общество

Подтвердить членство
или вступить в общество